Upstream Bio, a biotech firm, prices its IPO at $17/share for 15M shares, aiming for $255M, with verekitug targeting COPD.

Upstream Bio, a biotech firm focused on inflammatory diseases, has priced its initial public offering (IPO) at $17 per share for 15 million shares, aiming for $255 million in gross proceeds. Shares will debut on the Nasdaq under the ticker "UPB" on October 11, 2024. The company is developing verekitug, a monoclonal antibody targeting a key inflammatory cytokine, with plans to pursue trials for chronic obstructive pulmonary disease.

October 11, 2024
15 Articles

Further Reading